Synopsis
Synopsis
0
JDMF
0
EU WC
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-
2. Alpha 6 Deoxyoxytetracycline
3. Alpha-6-deoxyoxytetracycline
4. Atridox
5. Bmy 28689
6. Bmy-28689
7. Bmy28689
8. Bu 3839t
9. Bu-3839t
10. Bu3839t
11. Doryx
12. Doxycycline Calcium
13. Doxycycline Calcium Salt (1:2)
14. Doxycycline Chinoin
15. Doxycycline Hemiethanolate
16. Doxycycline Hyclate
17. Doxycycline Monohydrate
18. Doxycycline Monohydrochloride, 6 Epimer
19. Doxycycline Monohydrochloride, 6-epimer
20. Doxycycline Monohydrochloride, Dihydrate
21. Doxycycline Phosphate (1:1)
22. Doxycycline-chinoin
23. Hydramycin
24. Oracea
25. Periostat
26. Vibra Tabs
27. Vibra-tabs
28. Vibramycin
29. Vibramycin Novum
30. Vibravenos
1. 564-25-0
2. Vibramycin
3. Doxytetracycline
4. Doxycycline (anhydrous)
5. Doxiciclina
6. Doxycyclinum
7. Monodox
8. Doxycycline Hyclate
9. Doxycycline Anhydrous
10. 6alpha-deoxy-5-oxytetracycline
11. 5-hydroxy-alpha-6-deoxytetracycline
12. Vibramycine
13. Doxychel
14. 6-alpha-deoxy-5-oxytetracycline
15. Doxycyclin
16. Alpha-6-deoxy-5-hydroxytetracycline
17. Bmy-28689
18. Anhydrous Doxycycline
19. Liviatin
20. Doxycycline (inn)
21. Doxy-caps
22. Deoxymykoin
23. Dossiciclina
24. Doxitard
25. Doxivetin
26. Doxycen
27. Investin
28. Chebi:50845
29. Doxy-puren
30. Alpha-doxycycline
31. Doxy-tabs
32. Alpha-6-deoxyoxytetracycline
33. Mmv000011
34. (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
35. Doxysol
36. Jenacyclin
37. 6-deoxyoxytetracycline
38. Dossiciclina [dcit]
39. Doxiciclina [italian]
40. Doxycycline [inn]
41. (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
42. 2-naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s,4ar,5s,5ar,6r,12as)-
43. Doxycyclinum [inn-latin]
44. Doxycycline (internal Use)
45. Doxiciclina [inn-spanish]
46. 334895s862
47. Bu-3839t
48. Zenavod
49. Doxcycline Anhydrous
50. Oxytetracycline, 6-deoxy-
51. Doxycycline (tn)
52. Doxychel (tn)
53. Vivox (*hyclate)
54. Dmsc (*fosfatex)
55. Nsc633557
56. Hsdb 3071
57. Monodox (*monohydrate)
58. Bmy28689
59. Bu 3839t
60. 24390-14-5
61. Einecs 209-271-1
62. Bmy 28689
63. Vibramycin (*monohydrate)
64. 4-epioxytetracycline, 6-deoxy-
65. Gs-3065 (*monohydrate)
66. Doxycycline [usan:inn:ban]
67. Sr-01000075844
68. Unii-334895s862
69. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-
70. Ab08 (*fosfatex)
71. Spectrum_000807
72. (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamidehydrochloride
73. Spectrum2_000143
74. Spectrum3_000408
75. Spectrum4_000527
76. Spectrum5_000947
77. Doxycycline [hsdb]
78. Upcmld-dp021
79. Vibramycin, Doxytetracycline
80. Chembl1433
81. Lopac0_000405
82. Schembl40930
83. Schembl66828
84. Bspbio_001936
85. Doxycycline [who-dd]
86. Kbiogr_001133
87. Kbioss_001287
88. Bidd:gt0146
89. Divk1c_000345
90. Spbio_000246
91. Chembl436921
92. Gtpl6464
93. Schembl1176275
94. Dtxsid0037653
95. Schembl17826665
96. Schembl19270298
97. Schembl21753474
98. Upcmld-dp021:001
99. Bcbcmap01_000024
100. Kbio1_000345
101. Kbio2_001287
102. Kbio2_003855
103. Kbio2_006423
104. Kbio3_001156
105. Dtxsid80992212
106. Ninds_000345
107. Doxycycline Anhydrous [mi]
108. Hms2090e06
109. Doxytetracycline; Doxycycline
110. Hy-n0565
111. Lmpk07000001
112. S5159
113. Zinc16052277
114. Anhydrous Doxycycline [mart.]
115. Akos015900372
116. Zinc100056779
117. Zinc100302137
118. Zinc100611210
119. Zinc109562088
120. Ccg-204498
121. Db00254
122. Sdccgsbi-0050391.p005
123. Idi1_000345
124. Smp1_000107
125. Ncgc00161602-01
126. Ncgc00161602-03
127. Ncgc00161602-04
128. Ncgc00161602-05
129. Ncgc00161602-07
130. Ncgc00161602-14
131. Ncgc00188979-01
132. (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
133. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s,4ar,5s,5ar,6r,12as)
134. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s,4ar,5s,5ar,6r,12as)-
135. 2-naphthacenecarboxamide, 4-alpha-s-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,11,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dioxo-
136. As-13499
137. Sbi-0050391.p004
138. Cs-0009105
139. C06973
140. D07876
141. Ab00053465-03
142. Ab00053465_04
143. Ab00053465_05
144. 564d250
145. A817263
146. Doxycycline, Antibiotic For Culture Media Use Only
147. Q422442
148. Sr-01000075844-7
149. Vibramycin;doxytetracycline;doxiciclina;doxycyclinum
150. W-105517
151. Sr-01000075844-18
152. (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
153. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,6.alpha.,12a.alpha.))-
154. 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboximidic Acid
155. 7164-70-7
| Molecular Weight | 444.4 g/mol |
|---|---|
| Molecular Formula | C22H24N2O8 |
| XLogP3 | -0.7 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 2 |
| Exact Mass | 444.15326573 g/mol |
| Monoisotopic Mass | 444.15326573 g/mol |
| Topological Polar Surface Area | 182 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 956 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 18 | |
|---|---|
| Drug Name | Atridox |
| PubMed Health | Doxycycline (By mouth) |
| Drug Classes | Amebicide, Amebicide, Intestinal, Antiacne, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent |
| Drug Label | Doxycycline is a broad-spectrum antibacterial synthetically derived from oxytetracycline. Monodox 100 mg, 75 mg, and 50 mg capsules contain doxycycline monohydrate equivalent to 100 mg, 75 mg, or 50 mg of doxycycline for oral administration. The chem... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | System, extended release |
| Route | Periodontal |
| Strength | 50mg |
| Market Status | Prescription |
| Company | Tolmar |
| 2 of 18 | |
|---|---|
| Drug Name | Doryx |
| PubMed Health | Doxycycline (By mouth) |
| Drug Classes | Amebicide, Amebicide, Intestinal, Antiacne, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | eq 100mg base; eq 80mg base; eq 200mg base; eq 150mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Mayne Pharma |
| 3 of 18 | |
|---|---|
| Drug Name | Doxy 100 |
| PubMed Health | Doxycycline (Subgingival) |
| Drug Classes | Antibacterial |
| Drug Label | DORYX Capsules contain specially coated pellets of doxycycline hyclate, a broad-spectrum antibiotic synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration.The structural formula for doxycycline hyclate is... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 100mg base/vial |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 4 of 18 | |
|---|---|
| Drug Name | Doxycycline |
| PubMed Health | Doxycycline |
| Drug Classes | Amebicide, Amebicide, Intestinal, Antiacne, Antibacterial, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent |
| Drug Label | Doxycycline for Injection, USP is a sterile, lyophilized powder prepared from a solution of doxycycline hyclate, ascorbic acid and mannitol in Water for Injection. Doxycycline hyclate is a broad spectrum antibiotic derived from oxytetracycline. It is... |
| Active Ingredient | Doxycycline; Doxycycline hyclate |
| Dosage Form | Injectable; Tablet; Capsule; For suspension |
| Route | oral; Injection; Oral |
| Strength | eq 100mg base; eq 50mg base; eq 150mg base; 40mg; eq 25mg base/5ml; eq 75mg base; eq 100mg base/vial |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Ranbaxy; Lannett; Eurohlth Intl; Lupin; Agila Speclts; Chartwell Life Sci; Mylan; Par Pharm; Impax Labs; Heritage Pharms |
| 5 of 18 | |
|---|---|
| Drug Name | Doxycycline hyclate |
| PubMed Health | Doxycycline (Injection) |
| Drug Classes | Antibiotic, Antimalarial, Antiprotozoal |
| Drug Label | Doxycycline hyclate is a broad-spectrum antibiotic synthetically derived from oxytetracycline. The structural formula is as follows:with a molecular formula of C22H24N2O8H2O and a molecular weight of 462.46. The chemical designation for doxycycline i... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Tablet; Capsule, delayed release; Capsule; Tablet, delayed release |
| Route | Oral |
| Strength | eq 100mg base; eq 50mg base; eq 150mg base; eq 20mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Corepharma; Mutual Pharma; Vintage Pharms; Mylan Pharms; Blu Caribe; Ivax Sub Teva Pharms; Actavis Elizabeth; Larken Labs; Lannett; Mutual Pharm; Actavis Labs Fl; Medicis; Chartwell Life Sci; Hikma Pharms; Mylan; Impax Labs; Heritage Pharms |
| 6 of 18 | |
|---|---|
| Drug Name | Monodox |
| Drug Label | Vibramycin is an antibacterial drug synthetically derived from oxytetracycline, and is available as Vibramycin Monohydrate (doxycycline monohydrate); Vibramycin Hyclate and Vibra-Tabs (doxycycline hydrochloride hemiethanolate hemihydrate); and Vibram... |
| Active Ingredient | Doxycycline |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | eq 100mg base; eq 50mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Aqua Pharms |
| 7 of 18 | |
|---|---|
| Drug Name | Oracea |
| PubMed Health | Doxycycline |
| Drug Classes | Amebicide, Amebicide, Intestinal, Antiacne, Antibacterial, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent |
| Drug Label | Doxycycline hyclate is a broad-spectrum antibiotic synthetically derived from oxytetracycline. The structural formula is as follows:with a molecular formula of C22H24N2O8H2O and a molecular weight of 462.46. The chemical designation for doxycycline i... |
| Active Ingredient | Doxycycline |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 40mg |
| Market Status | Prescription |
| Company | Galderma Labs |
| 8 of 18 | |
|---|---|
| Drug Name | Periostat |
| PubMed Health | Doxycycline |
| Drug Classes | Amebicide, Amebicide, Intestinal, Antiacne, Antibacterial, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent |
| Drug Label | ORACEA (doxycycline, USP) Capsules 40 mg are hard gelatin capsule shells filled with two types of doxycycline beads (30 mg immediate release and 10 mg delayed release) that together provide a dose of 40 mg of anhydrous doxycycline (C22H24N2O8).The st... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 20mg base |
| Market Status | Prescription |
| Company | Galderma Labs |
| 9 of 18 | |
|---|---|
| Drug Name | Vibramycin |
| Active Ingredient | Doxycycline calcium; Doxycycline hyclate; Doxycycline |
| Dosage Form | Capsule; Suspension; For suspension |
| Route | Oral |
| Strength | eq 100mg base; eq 50mg base; eq 50mg base/5ml; eq 25mg base/5ml |
| Market Status | Prescription |
| Company | Pfizer |
| 10 of 18 | |
|---|---|
| Drug Name | Atridox |
| PubMed Health | Doxycycline (By mouth) |
| Drug Classes | Amebicide, Amebicide, Intestinal, Antiacne, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent |
| Drug Label | Doxycycline is a broad-spectrum antibacterial synthetically derived from oxytetracycline. Monodox 100 mg, 75 mg, and 50 mg capsules contain doxycycline monohydrate equivalent to 100 mg, 75 mg, or 50 mg of doxycycline for oral administration. The chem... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | System, extended release |
| Route | Periodontal |
| Strength | 50mg |
| Market Status | Prescription |
| Company | Tolmar |
| 11 of 18 | |
|---|---|
| Drug Name | Doryx |
| PubMed Health | Doxycycline (By mouth) |
| Drug Classes | Amebicide, Amebicide, Intestinal, Antiacne, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | eq 100mg base; eq 80mg base; eq 200mg base; eq 150mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Mayne Pharma |
| 12 of 18 | |
|---|---|
| Drug Name | Doxy 100 |
| PubMed Health | Doxycycline (Subgingival) |
| Drug Classes | Antibacterial |
| Drug Label | DORYX Capsules contain specially coated pellets of doxycycline hyclate, a broad-spectrum antibiotic synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration.The structural formula for doxycycline hyclate is... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 100mg base/vial |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 13 of 18 | |
|---|---|
| Drug Name | Doxycycline |
| PubMed Health | Doxycycline |
| Drug Classes | Amebicide, Amebicide, Intestinal, Antiacne, Antibacterial, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent |
| Drug Label | Doxycycline for Injection, USP is a sterile, lyophilized powder prepared from a solution of doxycycline hyclate, ascorbic acid and mannitol in Water for Injection. Doxycycline hyclate is a broad spectrum antibiotic derived from oxytetracycline. It is... |
| Active Ingredient | Doxycycline; Doxycycline hyclate |
| Dosage Form | Injectable; Tablet; Capsule; For suspension |
| Route | oral; Injection; Oral |
| Strength | eq 100mg base; eq 50mg base; eq 150mg base; 40mg; eq 25mg base/5ml; eq 75mg base; eq 100mg base/vial |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Ranbaxy; Lannett; Eurohlth Intl; Lupin; Agila Speclts; Chartwell Life Sci; Mylan; Par Pharm; Impax Labs; Heritage Pharms |
| 14 of 18 | |
|---|---|
| Drug Name | Doxycycline hyclate |
| PubMed Health | Doxycycline (Injection) |
| Drug Classes | Antibiotic, Antimalarial, Antiprotozoal |
| Drug Label | Doxycycline hyclate is a broad-spectrum antibiotic synthetically derived from oxytetracycline. The structural formula is as follows:with a molecular formula of C22H24N2O8H2O and a molecular weight of 462.46. The chemical designation for doxycycline i... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Tablet; Capsule, delayed release; Capsule; Tablet, delayed release |
| Route | Oral |
| Strength | eq 100mg base; eq 50mg base; eq 150mg base; eq 20mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Corepharma; Mutual Pharma; Vintage Pharms; Mylan Pharms; Blu Caribe; Ivax Sub Teva Pharms; Actavis Elizabeth; Larken Labs; Lannett; Mutual Pharm; Actavis Labs Fl; Medicis; Chartwell Life Sci; Hikma Pharms; Mylan; Impax Labs; Heritage Pharms |
| 15 of 18 | |
|---|---|
| Drug Name | Monodox |
| Drug Label | Vibramycin is an antibacterial drug synthetically derived from oxytetracycline, and is available as Vibramycin Monohydrate (doxycycline monohydrate); Vibramycin Hyclate and Vibra-Tabs (doxycycline hydrochloride hemiethanolate hemihydrate); and Vibram... |
| Active Ingredient | Doxycycline |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | eq 100mg base; eq 50mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Aqua Pharms |
| 16 of 18 | |
|---|---|
| Drug Name | Oracea |
| PubMed Health | Doxycycline |
| Drug Classes | Amebicide, Amebicide, Intestinal, Antiacne, Antibacterial, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent |
| Drug Label | Doxycycline hyclate is a broad-spectrum antibiotic synthetically derived from oxytetracycline. The structural formula is as follows:with a molecular formula of C22H24N2O8H2O and a molecular weight of 462.46. The chemical designation for doxycycline i... |
| Active Ingredient | Doxycycline |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 40mg |
| Market Status | Prescription |
| Company | Galderma Labs |
| 17 of 18 | |
|---|---|
| Drug Name | Periostat |
| PubMed Health | Doxycycline |
| Drug Classes | Amebicide, Amebicide, Intestinal, Antiacne, Antibacterial, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent |
| Drug Label | ORACEA (doxycycline, USP) Capsules 40 mg are hard gelatin capsule shells filled with two types of doxycycline beads (30 mg immediate release and 10 mg delayed release) that together provide a dose of 40 mg of anhydrous doxycycline (C22H24N2O8).The st... |
| Active Ingredient | Doxycycline hyclate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 20mg base |
| Market Status | Prescription |
| Company | Galderma Labs |
| 18 of 18 | |
|---|---|
| Drug Name | Vibramycin |
| Active Ingredient | Doxycycline calcium; Doxycycline hyclate; Doxycycline |
| Dosage Form | Capsule; Suspension; For suspension |
| Route | Oral |
| Strength | eq 100mg base; eq 50mg base; eq 50mg base/5ml; eq 25mg base/5ml |
| Market Status | Prescription |
| Company | Pfizer |
Antibiotics, Tetracycline
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
AGAINST GRAM-POSITIVE BACTERIA IT IS ABOUT TWICE AS POTENT AS TETRACYCLINE, EXCEPT THAT IT IS UP TO 10 TIMES AS POTENT AGAINST STREP VIRIDANS. FURTHERMORE, STRAINS OF STREP FAECALIS THAT ARE RESISTANT TO OTHER TETRACYCLINES MAY BE SENSITIVE TO DOXYCYCLINE.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1140
DOSE OF DOXYCYCLINE FOR ADULTS IS 100 MG EVERY 12 HR DURING FIRST 24 HR, FOLLOWED BY 100 MG ONCE DAY, OR TWICE DAILY WHEN SEVERE INFECTION IS PRESENT. CHILDREN OVER 8 YR SHOULD RECEIVE 4-5 MG/KG/DAY, DIVIDED INTO 2 EQUAL DOSES GIVEN @ 12 HR INTERVAL DURING FIRST DAY, AFTER WHICH SINGLE DOSE OF HALF THIS AMT IS ADMIN.
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1120
AFFINITY OF DOXYCYCLINE FOR METALLIC IONS MAY NOT BE AS GREAT AS THAT OF OTHER TETRACYCLINES SINCE IT CAN BE GIVEN WITH FOOD OR MILK WITHOUT SIGNIFICANT INACTIVATION OR IMPAIRMENT OF ABSORPTION.
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 746
For more Therapeutic Uses (Complete) data for DOXYCYCLINE (27 total), please visit the HSDB record page.
TETRACYCLINES SHOULD NOT BE ADMIN TO PREGNANT OR NURSING WOMEN & CHILDREN UNDER 8 YR UNLESS THERE ARE COMPELLING REASONS TO DO SO.
American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association, 1991., p. 1298
TREATMENT OF PREGNANT PATIENTS ... MAY PRODUCE DISCOLORATION OF TEETH IN THEIR OFFSPRING. ... CHILDREN UP TO 8 YR OLD MAY BE SUSCEPTIBLE ... TETRACYCLINES ARE DEPOSITED IN SKELETON DURING GESTATION. ... 40% DEPRESSION OF BONE GROWTH ... DEMONSTRATED IN PREMATURE INFANTS TREATED WITH THESE AGENTS. /TETRACYCLINES/
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1122
TETRACYCLINES POSE SPECIAL DANGER IN PREGNANT WOMEN, WITH RESPECT TO POSSIBLE HEPATIC INJURY, PARTICULARLY IF USED FOR TREATMENT OF PYELONEPHRITIS, RELATIVELY COMMON OCCURRENCE IN SUCH PATIENTS INDEED, FATALITIES HAVE OCCURRED. /TETRACYCLINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1188
IT SHOULD BE EMPHASIZED THAT CROSS-SENSITIZATION AMONG VARIOUS TETRACYCLINES IS COMMON.
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1122
For more Drug Warnings (Complete) data for DOXYCYCLINE (12 total), please visit the HSDB record page.
Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria. A complete list of organisms is available in the FDA label and in the "indications" section of this drug entry. The following are some of the major infections that may be treated with doxycycline: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (ornithosis) caused by Chlamydia psittaci Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis Nongonococcal urethritis caused by Ureaplasma urealyticum Relapsing fever due to Borrelia recurrentis **A note regarding anti-microbial resistance** It is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection. Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracyclines. Therefore, tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible.
FDA Label
Treatment of periodontal disease in dogs.
Periodontal pocket probing depths > =4 mm are evidence of disease that may be responsive to treatment with the Doxirobe Gel. Use of this product as directed should result in attachment level gains, periodontal pocket depth reductions, local antimicrobial effect and improved gingival health. Noticeable improvements in these parameters should be evident within 2-4 weeks following treatment. The response in individual dogs is dependent on the severity of the condition and rigor of adjunctive therapy.
The tetracyclines, including doxycycline, are mainly bacteriostatic and are thought to exert antimicrobial effects by the inhibition of protein synthesis. Bacteriostatic antibiotics suppress the growth of bacteria, or keep them in the stationary phase of growth. The tetracyclines, including doxycycline, have a similar antimicrobial spectrum of activity against a variety of gram-positive and gram-negative microorganisms, treating numerous infectious diseases. Cross-resistance of these microorganisms to tetracyclines is a common occurrence. Doxycycline shows favorable intra-cellular penetration, with bacteriostatic activity on a wide range of bacteria. Doxycycline has antiparasitic effects,,. In addition to the above effects, this drug has demonstrated anti-inflammatory actions, which may help to manage inflammatory conditions such as rosacea.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Antimalarials
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)
QJ01AA02
J01AA02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A01 - Stomatological preparations
A01A - Stomatological preparations
A01AB - Antiinfectives and antiseptics for local oral treatment
A01AB22 - Doxycycline
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01A - Tetracyclines
J01AA - Tetracyclines
J01AA02 - Doxycycline
Absorption
Tetracyclines, such as doxycycline, are readily absorbed and are bound to plasma proteins by varying degrees. Doxycycline is almost completely absorbed after oral administration. This drug is highly lipid soluble and has a low affinity for calcium binding. Absorption is not significantly affected by the concomitant ingestion of food or milk. Peak serum levels of approximately 2.6 mcg/ml are reached at 2 hours following a 200 mg tablet oral dose.
Route of Elimination
Mainly the urine and feces as active and unchanged drug. Between 40% and 60% of an administered dose can be accounted for in the urine by 92 hours, and approximately 30% can be accounted for in the feces.
Volume of Distribution
Doxycycline diffuses readily into most body tissues, fluid and/or cavities and the volume of distribution has been measured as 0.7 L/kg.
Clearance
The excretion of doxycycline by the kidney is about 40% over 72 hours in individuals with normal kidney function (creatinine clearance approximately 75 mL/min). This rate may fall as low as 1-5% over 72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Some clinical studies have shown no major difference in serum half-life of doxycycline (range 18-22 hours) in patients with normal and severely impaired renal function. Hemodialysis does not affect serum half-life of doxycycline.
RELATIVE INSENSITIVITY OF DOXYCYCLINE PHARMACOKINETICS TO RENAL INSUFFICIENCY HAS ... BEEN DEMONSTRATED IN HUMANS & APPEARS TO BE ASSOC WITH INCR FECAL EXCRETION OWING TO DIFFUSION OF DRUG INTO LUMEN OF SMALL INTESTINE. ... RENAL CLEARANCE OF ACTIVE ANTIBIOTIC IS ... 20 ... ML/MIN FOR DOXYCYCLINE ... .
The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 174
SERUM LEVELS OF DOXYCYCLINE ARE EQUIV WHETHER DRUG IS DOSED BY IV OR PER OS ROUTE. AFTER MULTIPLE DAILY IV DOSES OF 200 MG, SERUM LEVELS ... FLUCTUATED BETWEEN 5-6 & 1-2 UG/ML, WHICH IS ABOVE MIN INHIBITORY CONCN FOR MOST SUSCEPTIBLE PATHOGENS.
The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 174
URINARY EXCRETION OF ... DOXYCYCLINE IS INCR @ HIGH URINARY PH VALUES. ALKALINE TREATMENT OF SUBJECTS RESULTED IN 24% INCR IN CUMULATIVE URINARY TETRACYCLINE EXCRETION COMPARED WITH ACID TREATMENT (P< 0.05) & 54% INCR FOR DOXYCYCLINE (P LESS THAN 0.05). RENAL CLEARANCE ... INCR DURING ALKALINE TREATMENT ... .
The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 173
... MORE COMPLETELY ABSORBED AFTER ORAL ADMIN THAN OTHER TETRACYCLINES ... IN PLASMA, IT IS ABOUT 90% PROTEIN BOUND, WHICH IS HIGHEST DEGREE FOR ANY OF TETRACYCLINES.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1140
For more Absorption, Distribution and Excretion (Complete) data for DOXYCYCLINE (20 total), please visit the HSDB record page.
Doxycycline is metabolized in the liver and gastrointestinal tract and concentrated in bile,. Major metabolic pathways of doxycycline have not been identified, however, enzyme inducers have been found to decrease the half-life of doxycycline.
/DOXYCYCLINE/ IS EXCRETED IN FECES (UP TO 90%) AS INACTIVE CONJUGATE OR PERHAPS AS CHELATE.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1186
Although it was previously suggested that doxycycline is partially metabolized in the liver, recent studies indicate that the drug is not metabolized but is partially deactivated in the intestine by chelate formation.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 93. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1993 (Plus Supplements, 1993)., p. 319
16.33 hr ( 4.53 sd).
DOXYCYCLINE: ROUTES OF EXCRETION: HEPATIC, RENAL; NORMAL HALF-LIFE: 20 HR; MAINTENANCE DOSE INTERVALS: 12-24 HR.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1109
DOXYCYCLINE IS LONG-ACTING, HAVING SERUM HALF-LIFE OF 15-17 HR AFTER INITIAL DOSE & ABOUT 22 HR AFTER 4TH DAY OF TREATMENT.
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 736
The serum half-life of doxycycline is 14-17 hr after a single dose and 22-24 hr after multiple doses in patients with normal renal function. In patients with severe renal impairment, the serum half-life of doxycycline is reported to be 18-26 hr after a single dose, and 20-30 hr after multiple doses. It appears that serum half-life of doxycycline is not altered in patients undergoing hemodialysis. In patients with normal renal function, approximately 20-26% of a single oral or iv dose of doxycycline is excreted in urine and 20-40% is excreted in feces within 48 hr as active drug. In patients with creatinine clearances less than 10 ml/minute, the fraction of doxycycline excreted in urine within 72 hr may decrease to about 1-5%.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 93. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1993 (Plus Supplements, 1993)., p. 319
In bacterial replication, an interaction that is important for translation initiation of proteins occurs at the 3 end of the 16S rRNA, found on the ribosome on the 30S subunit,,. The 30S subunit is the smaller subunit of the ribosome of prokaryotes, including bacteria. Tetracyclines such as doxycycline are thought to inhibit translation by binding to the 16S rRNA portion of the ribosome, preventing binding of tRNA to the RNA-30S bacterial ribosomal subunit, which is necessary for the delivery of amino acids for protein synthesis. As a result of the above actions, the initiation of protein synthesis by polyribosome formation is blocked. This stops the replication of bacteria and produces a bacteriostatic effect.
TETRACYCLINES INHIBIT BACTERIAL PROTEIN SYNTHESIS. ... ONCE TETRACYCLINES GAIN ACCESS TO THE BACTERIAL CELL, THEY BIND PRINCIPALLY TO 30 S SUBUNITS OF BACTERIAL RIBOSOMES. THEY APPEAR TO PREVENT ACCESS OF AMINOACYL T-RNA TO M-RNA-RIBOSOME COMPLEX. ... ONLY SMALL PORTION OF DRUG IS IRREVERSIBLY BOUND, & INHIBITORY EFFECTS OF THE TETRACYCLINESARE REVERSIBLE WHEN THE DRUG IS REMOVED. /TETRACYCLINES/
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1118
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Oracea-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Lead Product(s): Doxycycline
Therapeutic Area: Dermatology Brand Name: Oracea-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2024
Lead Product(s) : Doxycycline
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg in the U.S.
Details : Oracea-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Product Name : Oracea-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
May 03, 2024
Details:
Doxy 100-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Lead Product(s): Doxycycline
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2024
Lead Product(s) : Doxycycline
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Endo Launches Doxycycline for Injection, USP
Details : Doxy 100-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 10, 2024
Details:
D-PLEX (doxycycline) is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent surgical site infections (SSIs).
Lead Product(s): Doxycycline
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Lead Product(s) : Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
Details : D-PLEX (doxycycline) is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent surgical site infections (SSIs).
Product Name : D-PLEX100
Product Type : Small molecule
Upfront Cash : Not Applicable
February 12, 2024
Details:
Doxycycline for Injection, USP is a Protein 30S ribosomal subunit inhibitor, which is used for prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Lead Product(s): Doxycycline
Therapeutic Area: Infections and Infectious Diseases Brand Name: Doxycycline-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2023
Lead Product(s) : Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Piramal Critical Care Announces the U.S. Launch of Doxycycline for Injection, USP
Details : Doxycycline for Injection, USP is a Protein 30S ribosomal subunit inhibitor, which is used for prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Product Name : Doxycycline-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
June 16, 2023
Details:
D-PLEX100 (doxycycline), is novel product candidate designed to provide local prolonged anti-bacterial activity directly at surgical site to prevent SSI and,has shown result by significantly decreasing surgical site infections in abdominal surgery with colorectal resection.
Lead Product(s): Doxycycline
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Lead Product(s) : Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society fo...
Details : D-PLEX100 (doxycycline), is novel product candidate designed to provide local prolonged anti-bacterial activity directly at surgical site to prevent SSI and,has shown result by significantly decreasing surgical site infections in abdominal surgery with c...
Product Name : D-PLEX100
Product Type : Small molecule
Upfront Cash : Not Applicable
September 12, 2022
Details:
D-PLEX100 (doxycycline), PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Lead Product(s): Doxycycline
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Lead Product(s) : Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : D-PLEX100 (doxycycline), PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Product Name : D-PLEX100
Product Type : Small molecule
Upfront Cash : Not Applicable
May 23, 2022
Details:
Proceeds from the loan will be used to support global commercialization preparations for the launch of D-PLEX100 for the prevention of abdominal soft tissue surgical site infections (SSIs), as well as further advancement of PolyPid’s OncoPLEX development platform.
Lead Product(s): Doxycycline
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Kreos Capital VI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 06, 2022
Lead Product(s) : Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Kreos Capital VI
Deal Size : Undisclosed
Deal Type : Financing
PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility
Details : Proceeds from the loan will be used to support global commercialization preparations for the launch of D-PLEX100 for the prevention of abdominal soft tissue surgical site infections (SSIs), as well as further advancement of PolyPid’s OncoPLEX developme...
Product Name : D-PLEX100
Product Type : Small molecule
Upfront Cash : Undisclosed
April 06, 2022
Details:
The designation is based on conclusive positive results from a Phase 2 trial of D-PLEX100 for the prevention of surgical site infections in abdominal colorectal surgery. D-PLEX100 significantly decreased in SSIs of 59% in the Intent to Treat population.
Lead Product(s): Doxycycline
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Lead Product(s) : Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX₁₀₀ for the Prevention o...
Details : The designation is based on conclusive positive results from a Phase 2 trial of D-PLEX100 for the prevention of surgical site infections in abdominal colorectal surgery. D-PLEX100 significantly decreased in SSIs of 59% in the Intent to Treat population.
Product Name : D-PLEX100
Product Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2020
Details:
Research found that eight-week course of the proven leprosy drug dapsone combined with doxycycline and rifampin is effective in improving symptoms in 98% of patients suffering from chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS).
Lead Product(s): Dapsone,Doxycycline,Rifampicin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Lead Product(s) : Dapsone,Doxycycline,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Research found that eight-week course of the proven leprosy drug dapsone combined with doxycycline and rifampin is effective in improving symptoms in 98% of patients suffering from chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS).
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
October 28, 2020
Details:
PolyPid's D-PLEX100 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the prevention of post abdominal surgery incisional infections.
Lead Product(s): Doxycycline
Therapeutic Area: Infections and Infectious Diseases Brand Name: D-PLEX100
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Lead Product(s) : Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PolyPid Granted Fast Track Designation from FDA for D-PLEX₁₀₀ for Prevention of Surgical Sit...
Details : PolyPid's D-PLEX100 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the prevention of post abdominal surgery incisional infections.
Product Name : D-PLEX100
Product Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - CAPSULE;ORAL - EQ 100MG BASE
USFDA APPLICATION NUMBER - 50641
DOSAGE - CAPSULE;ORAL - EQ 150MG BASE
USFDA APPLICATION NUMBER - 50641
DOSAGE - CAPSULE;ORAL - EQ 50MG BASE
USFDA APPLICATION NUMBER - 50641
DOSAGE - CAPSULE;ORAL - EQ 75MG BASE
USFDA APPLICATION NUMBER - 50641
DOSAGE - CAPSULE;ORAL - 40MG
USFDA APPLICATION NUMBER - 50805
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seqens
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vertellus
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Controlled & Modified Release
Disintegrants & Superdisintegrants
Thickeners and Stabilizers
Solubilizers
Direct Compression
Granulation
Film Formers & Plasticizers
Parenteral
Taste Masking
Topical
Lubricants & Glidants
Co-Processed Excipients
Chewable & Orodispersible Aids
Empty Capsules
Emulsifying Agents
Rheology Modifiers
API Stability Enhancers
Surfactant & Foaming Agents
Coloring Agents
Vegetarian Capsules
Soft Gelatin
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
79
PharmaCompass offers a list of Doxycycline API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Doxycycline manufacturer or Doxycycline supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Doxycycline manufacturer or Doxycycline supplier.
PharmaCompass also assists you with knowing the Doxycycline API Price utilized in the formulation of products. Doxycycline API Price is not always fixed or binding as the Doxycycline Price is obtained through a variety of data sources. The Doxycycline Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Doxycycline anhydrous manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Doxycycline anhydrous, including repackagers and relabelers. The FDA regulates Doxycycline anhydrous manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Doxycycline anhydrous API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Doxycycline anhydrous manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Doxycycline anhydrous supplier is an individual or a company that provides Doxycycline anhydrous active pharmaceutical ingredient (API) or Doxycycline anhydrous finished formulations upon request. The Doxycycline anhydrous suppliers may include Doxycycline anhydrous API manufacturers, exporters, distributors and traders.
click here to find a list of Doxycycline anhydrous suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Doxycycline anhydrous DMF (Drug Master File) is a document detailing the whole manufacturing process of Doxycycline anhydrous active pharmaceutical ingredient (API) in detail. Different forms of Doxycycline anhydrous DMFs exist exist since differing nations have different regulations, such as Doxycycline anhydrous USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Doxycycline anhydrous DMF submitted to regulatory agencies in the US is known as a USDMF. Doxycycline anhydrous USDMF includes data on Doxycycline anhydrous's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Doxycycline anhydrous USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Doxycycline anhydrous suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Doxycycline anhydrous Drug Master File in Korea (Doxycycline anhydrous KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Doxycycline anhydrous. The MFDS reviews the Doxycycline anhydrous KDMF as part of the drug registration process and uses the information provided in the Doxycycline anhydrous KDMF to evaluate the safety and efficacy of the drug.
After submitting a Doxycycline anhydrous KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Doxycycline anhydrous API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Doxycycline anhydrous suppliers with KDMF on PharmaCompass.
A Doxycycline anhydrous CEP of the European Pharmacopoeia monograph is often referred to as a Doxycycline anhydrous Certificate of Suitability (COS). The purpose of a Doxycycline anhydrous CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Doxycycline anhydrous EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Doxycycline anhydrous to their clients by showing that a Doxycycline anhydrous CEP has been issued for it. The manufacturer submits a Doxycycline anhydrous CEP (COS) as part of the market authorization procedure, and it takes on the role of a Doxycycline anhydrous CEP holder for the record. Additionally, the data presented in the Doxycycline anhydrous CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Doxycycline anhydrous DMF.
A Doxycycline anhydrous CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Doxycycline anhydrous CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Doxycycline anhydrous suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Doxycycline anhydrous as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Doxycycline anhydrous API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Doxycycline anhydrous as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Doxycycline anhydrous and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Doxycycline anhydrous NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Doxycycline anhydrous suppliers with NDC on PharmaCompass.
Doxycycline anhydrous Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Doxycycline anhydrous GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Doxycycline anhydrous GMP manufacturer or Doxycycline anhydrous GMP API supplier for your needs.
A Doxycycline anhydrous CoA (Certificate of Analysis) is a formal document that attests to Doxycycline anhydrous's compliance with Doxycycline anhydrous specifications and serves as a tool for batch-level quality control.
Doxycycline anhydrous CoA mostly includes findings from lab analyses of a specific batch. For each Doxycycline anhydrous CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Doxycycline anhydrous may be tested according to a variety of international standards, such as European Pharmacopoeia (Doxycycline anhydrous EP), Doxycycline anhydrous JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Doxycycline anhydrous USP).
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
